XML 43 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaborative Agreements Collaborative Agreements (Details) (USD $)
 3 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Sep. 30, 2013
Collaborative Arrangement, Product [Member]
Sep. 30, 2013
Roche [Member]
Collaborative Arrangement, Product [Member]
Dec. 31, 2013
Roche [Member]
Collaborative Arrangement, Product [Member]
Sep. 30, 2013
INO 1800 [Member]
Collaborative Arrangement, Product [Member]
Sep. 30, 2013
INO 5150 [Member]
Collaborative Arrangement, Product [Member]
Sep. 30, 2013
Nonsoftware License Arrangement [Member]
Option Right [Member]
Collaborative Arrangement, Product [Member]
Sep. 30, 2013
Nonsoftware License Arrangement [Member]
Joint Steering Committee Obligation [Member]
Collaborative Arrangement, Product [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                    
Upfront payment received                       $ 10,000,000 $ 10,000,000          
Anticipated development and regulatory event based payment receivable                         412,500,000          
Anticipated development and regulatory event based payment receivable milestones                         3,000,000          
Commercial event based payment received                         0          
Length of period after date of product first commercial sale to determine agreement in effect terms                         10 years          
Revenue recognized                             3,400,000 5,000,000    
Deferred revenue, additions                                 1,500,000 155,000
Revenue under collaborative research and development arrangements 822,217 8,388,760 14,311 14,259 14,296 22,495 20,907 24,838 9,239,547 82,536 156,397     9,200,000        
Revenue under collaborative research and development arrangements allocated to the licenses                           9,100,000        
Revenue under collaborative research and development arrangements allocated to research and development services and manufacturing                           84,000        
Deferred revenue                           $ 3,400,000